DERM Journey Medical Corporation
USHealthcareAs of 2026-07-10 16:00
Why DERM matters now
Journey Medical Corporation (DERM) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.91 with -1.29% on the session and $190.2M in market capitalization; recent performance reads 1-month +1.14% and YTD -19.33%.
The latest financial table shown here is Q1 2026, with revenue of $16.0M, net income of $-2.2M, and EPS of $-0.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.0%.
The latest indexable market news headline is "Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $11.75; recent insider activity includes Maraoui Claude filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.51
P/S
2.65
EV/EBITDA
-117.50
DCF Value
$-10.36
FCF Yield
-4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.4%
Operating Margin
-9.8%
Net Margin
-14.8%
ROE
-35.6%
ROA
-10.5%
ROIC
-11.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $16.0M | $-2.2M | $-0.08 |
| Q4 2025 | $16.1M | $-1.2M | $-0.05 |
| FY 2025 | $61.9M | $-11.4M | $-0.47 |
| Q3 2025 | $17.6M | $-2.3M | $-0.09 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$11.75
Target (Median)
$11.75
Target Range
$10.50 - $13.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
1.10
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.